Sami Uwaydat
Concepts (290)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Retinal Diseases | 11 | 2024 | 50 | 5.700 |
Why?
| Eye Injuries | 5 | 2024 | 25 | 3.330 |
Why?
| Visual Acuity | 15 | 2024 | 142 | 3.210 |
Why?
| Tomography, Optical Coherence | 19 | 2024 | 104 | 2.540 |
Why?
| Vitrectomy | 11 | 2024 | 60 | 2.420 |
Why?
| Retina | 9 | 2024 | 62 | 2.150 |
Why?
| Endophthalmitis | 4 | 2022 | 25 | 2.040 |
Why?
| Macular Degeneration | 3 | 2024 | 27 | 1.910 |
Why?
| Retinal Perforations | 3 | 2024 | 7 | 1.870 |
Why?
| Diabetic Retinopathy | 3 | 2024 | 39 | 1.790 |
Why?
| Retinal Dystrophies | 3 | 2023 | 6 | 1.760 |
Why?
| Macular Edema | 4 | 2023 | 28 | 1.620 |
Why?
| Retinal Degeneration | 4 | 2022 | 10 | 1.610 |
Why?
| Drug Implants | 5 | 2020 | 35 | 1.590 |
Why?
| Eye Proteins | 3 | 2023 | 17 | 1.570 |
Why?
| Chorioretinitis | 2 | 2022 | 9 | 1.540 |
Why?
| Fungemia | 2 | 2022 | 37 | 1.520 |
Why?
| Eye Infections, Fungal | 2 | 2022 | 19 | 1.510 |
Why?
| Eye Diseases | 4 | 2023 | 32 | 1.380 |
Why?
| Eye Infections, Bacterial | 3 | 2024 | 30 | 1.350 |
Why?
| Dexamethasone | 4 | 2020 | 424 | 1.320 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2024 | 483 | 1.180 |
Why?
| Humans | 61 | 2024 | 49922 | 1.150 |
Why?
| Fluorescein Angiography | 8 | 2024 | 33 | 1.100 |
Why?
| Fundus Oculi | 7 | 2024 | 25 | 0.980 |
Why?
| Intraoperative Complications | 4 | 2024 | 113 | 0.960 |
Why?
| Glucocorticoids | 5 | 2020 | 229 | 0.940 |
Why?
| Syphilis Serodiagnosis | 1 | 2024 | 4 | 0.940 |
Why?
| Treponema pallidum | 1 | 2024 | 10 | 0.930 |
Why?
| Myopia, Degenerative | 1 | 2024 | 1 | 0.920 |
Why?
| Amnion | 1 | 2024 | 9 | 0.920 |
Why?
| Burns, Chemical | 1 | 2024 | 9 | 0.920 |
Why?
| Syphilis | 1 | 2024 | 27 | 0.900 |
Why?
| Glaucoma, Open-Angle | 1 | 2024 | 21 | 0.900 |
Why?
| Retinal Vein Occlusion | 2 | 2023 | 14 | 0.880 |
Why?
| Charcot-Marie-Tooth Disease | 1 | 2022 | 8 | 0.800 |
Why?
| Retrospective Studies | 19 | 2024 | 6124 | 0.800 |
Why?
| Middle Aged | 21 | 2024 | 12289 | 0.800 |
Why?
| Genetic Testing | 2 | 2020 | 119 | 0.800 |
Why?
| Optic Atrophy | 1 | 2022 | 16 | 0.790 |
Why?
| Electroretinography | 8 | 2023 | 17 | 0.780 |
Why?
| Giant Cell Arteritis | 1 | 2021 | 12 | 0.760 |
Why?
| Databases, Factual | 2 | 2024 | 660 | 0.750 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2024 | 201 | 0.750 |
Why?
| Genetic Diseases, X-Linked | 1 | 2021 | 7 | 0.750 |
Why?
| Laser Coagulation | 1 | 2021 | 26 | 0.730 |
Why?
| Retinal Pigment Epithelium | 2 | 2022 | 11 | 0.730 |
Why?
| Multiple Sclerosis | 1 | 2021 | 63 | 0.730 |
Why?
| Manikins | 1 | 2021 | 35 | 0.720 |
Why?
| Lasers, Solid-State | 1 | 2021 | 32 | 0.720 |
Why?
| Diabetes Mellitus | 1 | 2024 | 279 | 0.710 |
Why?
| Intraocular Pressure | 3 | 2024 | 54 | 0.710 |
Why?
| Candidiasis | 1 | 2021 | 114 | 0.700 |
Why?
| Wounds, Nonpenetrating | 1 | 2021 | 81 | 0.700 |
Why?
| Choroidal Neovascularization | 2 | 2019 | 19 | 0.700 |
Why?
| Intravitreal Injections | 7 | 2023 | 33 | 0.700 |
Why?
| Anterior Chamber | 2 | 2023 | 6 | 0.680 |
Why?
| Surgical Instruments | 1 | 2019 | 27 | 0.670 |
Why?
| Male | 31 | 2024 | 25450 | 0.670 |
Why?
| Female | 26 | 2024 | 26571 | 0.640 |
Why?
| Endotamponade | 2 | 2017 | 8 | 0.630 |
Why?
| Gaucher Disease | 1 | 2018 | 14 | 0.610 |
Why?
| Eyelashes | 1 | 2018 | 3 | 0.610 |
Why?
| Eyelid Diseases | 1 | 2018 | 12 | 0.600 |
Why?
| Sulfur Hexafluoride | 1 | 2017 | 2 | 0.590 |
Why?
| Eye Diseases, Hereditary | 1 | 2017 | 5 | 0.580 |
Why?
| Inheritance Patterns | 1 | 2017 | 22 | 0.570 |
Why?
| Aged | 15 | 2024 | 9448 | 0.560 |
Why?
| Lenses | 1 | 2016 | 5 | 0.530 |
Why?
| Urinary Catheters | 1 | 2016 | 6 | 0.530 |
Why?
| Suction | 1 | 2016 | 23 | 0.530 |
Why?
| Mutation | 3 | 2022 | 1292 | 0.520 |
Why?
| Incidence | 4 | 2024 | 986 | 0.520 |
Why?
| Eye Injuries, Penetrating | 2 | 2015 | 14 | 0.500 |
Why?
| Bacillaceae | 1 | 2015 | 4 | 0.490 |
Why?
| Adult | 17 | 2024 | 13355 | 0.480 |
Why?
| Aspirin | 1 | 2016 | 111 | 0.480 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 122 | 0.480 |
Why?
| Choroid Neoplasms | 1 | 2014 | 6 | 0.460 |
Why?
| Wound Healing | 2 | 2016 | 201 | 0.460 |
Why?
| Ocular Hypotension | 1 | 2013 | 2 | 0.460 |
Why?
| Viscosupplements | 1 | 2013 | 14 | 0.450 |
Why?
| Orbital Neoplasms | 1 | 2014 | 31 | 0.450 |
Why?
| Antibodies, Monoclonal | 1 | 2018 | 457 | 0.450 |
Why?
| Head Injuries, Closed | 1 | 2013 | 8 | 0.450 |
Why?
| Hyaluronic Acid | 1 | 2013 | 35 | 0.440 |
Why?
| Disease Models, Animal | 2 | 2016 | 1411 | 0.430 |
Why?
| Retinitis Pigmentosa | 2 | 2023 | 8 | 0.430 |
Why?
| Physicians, Primary Care | 1 | 2013 | 46 | 0.420 |
Why?
| Sulfonamides | 1 | 2014 | 125 | 0.420 |
Why?
| Diabetes Complications | 1 | 2013 | 118 | 0.410 |
Why?
| Retinal Detachment | 2 | 2023 | 25 | 0.400 |
Why?
| Acute Disease | 3 | 2023 | 367 | 0.400 |
Why?
| Skin Neoplasms | 2 | 2014 | 487 | 0.400 |
Why?
| Phacoemulsification | 4 | 2024 | 36 | 0.390 |
Why?
| Pedigree | 3 | 2023 | 125 | 0.390 |
Why?
| Honey | 1 | 2011 | 6 | 0.390 |
Why?
| Keratitis | 1 | 2011 | 10 | 0.390 |
Why?
| Papilledema | 2 | 2022 | 27 | 0.380 |
Why?
| Indoles | 1 | 2014 | 273 | 0.380 |
Why?
| Clinical Competence | 2 | 2013 | 396 | 0.380 |
Why?
| Pseudomonas Infections | 1 | 2011 | 47 | 0.380 |
Why?
| Panuveitis | 2 | 2021 | 6 | 0.360 |
Why?
| Melanoma | 1 | 2014 | 281 | 0.360 |
Why?
| Attitude of Health Personnel | 1 | 2013 | 349 | 0.350 |
Why?
| Risk Factors | 5 | 2024 | 3604 | 0.340 |
Why?
| Antineoplastic Agents | 2 | 2018 | 1175 | 0.340 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 488 | 0.330 |
Why?
| Retinal Vessels | 3 | 2024 | 14 | 0.320 |
Why?
| Phenotype | 2 | 2021 | 728 | 0.300 |
Why?
| Scleral Buckling | 2 | 2023 | 5 | 0.300 |
Why?
| Fovea Centralis | 3 | 2022 | 5 | 0.290 |
Why?
| Ophthalmology | 3 | 2018 | 32 | 0.290 |
Why?
| Equipment Contamination | 1 | 2007 | 19 | 0.290 |
Why?
| Ophthalmologic Surgical Procedures | 1 | 2007 | 22 | 0.280 |
Why?
| Microscopy | 1 | 2007 | 58 | 0.280 |
Why?
| Child, Preschool | 5 | 2024 | 3878 | 0.270 |
Why?
| Child | 8 | 2024 | 6848 | 0.240 |
Why?
| Lens Subluxation | 1 | 2024 | 2 | 0.240 |
Why?
| Fractals | 1 | 2024 | 8 | 0.240 |
Why?
| Reagins | 1 | 2024 | 2 | 0.240 |
Why?
| Posterior Eye Segment | 1 | 2024 | 2 | 0.240 |
Why?
| Antibodies, Bacterial | 1 | 2024 | 27 | 0.230 |
Why?
| Subretinal Fluid | 1 | 2023 | 2 | 0.230 |
Why?
| Paracentesis | 1 | 2023 | 13 | 0.230 |
Why?
| Retinol-Binding Proteins | 1 | 2023 | 5 | 0.230 |
Why?
| Choroid | 2 | 2024 | 14 | 0.230 |
Why?
| Myopia | 1 | 2023 | 8 | 0.220 |
Why?
| Immunoglobulin G | 1 | 2024 | 184 | 0.220 |
Why?
| Retinoschisis | 1 | 2023 | 3 | 0.220 |
Why?
| Hemoglobin C | 1 | 2023 | 6 | 0.210 |
Why?
| Optic Nerve Injuries | 1 | 2022 | 7 | 0.210 |
Why?
| Young Adult | 5 | 2023 | 4031 | 0.210 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2020 | 183 | 0.210 |
Why?
| Thionucleotides | 1 | 2002 | 10 | 0.210 |
Why?
| Scotoma | 1 | 2021 | 7 | 0.190 |
Why?
| Macula Lutea | 1 | 2021 | 3 | 0.190 |
Why?
| Vision Disorders | 2 | 2022 | 59 | 0.190 |
Why?
| Albinism, Oculocutaneous | 1 | 2021 | 3 | 0.190 |
Why?
| Temporal Arteries | 1 | 2021 | 15 | 0.190 |
Why?
| Ophthalmoscopy | 1 | 2021 | 14 | 0.190 |
Why?
| Follow-Up Studies | 6 | 2023 | 2177 | 0.180 |
Why?
| Choroiditis | 1 | 2020 | 9 | 0.180 |
Why?
| Antiviral Agents | 1 | 2002 | 168 | 0.180 |
Why?
| Exons | 1 | 2021 | 96 | 0.180 |
Why?
| Infant | 3 | 2024 | 3574 | 0.180 |
Why?
| Internship and Residency | 2 | 2013 | 442 | 0.180 |
Why?
| Eye Abnormalities | 1 | 2020 | 24 | 0.170 |
Why?
| Hyperlipoproteinemia Type I | 1 | 2000 | 2 | 0.170 |
Why?
| Conjunctival Diseases | 1 | 2000 | 4 | 0.170 |
Why?
| Emergency Service, Hospital | 1 | 2024 | 487 | 0.170 |
Why?
| Eyeglasses | 1 | 2019 | 9 | 0.170 |
Why?
| Crohn Disease | 1 | 2020 | 90 | 0.170 |
Why?
| Vitreoretinal Surgery | 1 | 2019 | 8 | 0.170 |
Why?
| Disease Management | 1 | 2021 | 175 | 0.170 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 168 | 0.170 |
Why?
| Intraoperative Period | 1 | 2019 | 45 | 0.170 |
Why?
| Optic Disk | 1 | 2019 | 20 | 0.160 |
Why?
| Biopsy | 1 | 2021 | 591 | 0.160 |
Why?
| Pandemics | 1 | 2024 | 566 | 0.160 |
Why?
| Laser Therapy | 1 | 2019 | 84 | 0.160 |
Why?
| Amaurosis Fugax | 1 | 2018 | 3 | 0.160 |
Why?
| Vision, Ocular | 1 | 2018 | 9 | 0.160 |
Why?
| Glucosylceramidase | 1 | 2018 | 8 | 0.160 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 152 | 0.160 |
Why?
| Retinal Artery Occlusion | 1 | 2018 | 13 | 0.150 |
Why?
| Enzyme Replacement Therapy | 1 | 2018 | 17 | 0.150 |
Why?
| Visual Fields | 1 | 2018 | 36 | 0.150 |
Why?
| Vascular Malformations | 1 | 2020 | 98 | 0.150 |
Why?
| Fluocinolone Acetonide | 1 | 2017 | 5 | 0.150 |
Why?
| Prone Position | 1 | 2017 | 31 | 0.150 |
Why?
| Genes, Recessive | 1 | 2017 | 16 | 0.140 |
Why?
| Consanguinity | 1 | 2017 | 18 | 0.140 |
Why?
| Thrombolytic Therapy | 1 | 2018 | 110 | 0.140 |
Why?
| Uveitis | 1 | 2017 | 20 | 0.140 |
Why?
| Fibrinolytic Agents | 1 | 2018 | 125 | 0.140 |
Why?
| Heterozygote | 1 | 2017 | 81 | 0.140 |
Why?
| Recombinant Proteins | 1 | 2018 | 482 | 0.140 |
Why?
| Adolescent | 4 | 2022 | 6416 | 0.140 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 176 | 0.140 |
Why?
| Air | 1 | 2016 | 23 | 0.140 |
Why?
| Minerals | 1 | 2016 | 30 | 0.140 |
Why?
| Genetic Association Studies | 1 | 2017 | 115 | 0.140 |
Why?
| Patient Selection | 1 | 1998 | 254 | 0.130 |
Why?
| Vascular Surgical Procedures | 1 | 2018 | 164 | 0.130 |
Why?
| Sodium Chloride | 1 | 2016 | 56 | 0.130 |
Why?
| United States | 2 | 2024 | 4880 | 0.130 |
Why?
| Acetates | 1 | 2016 | 49 | 0.130 |
Why?
| Chemokine CCL2 | 1 | 2016 | 67 | 0.130 |
Why?
| Equipment Failure | 1 | 2016 | 63 | 0.130 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 234 | 0.130 |
Why?
| Animals | 5 | 2022 | 13100 | 0.130 |
Why?
| Eye Foreign Bodies | 1 | 2015 | 7 | 0.120 |
Why?
| Nevus of Ota | 1 | 2014 | 2 | 0.120 |
Why?
| Scleral Diseases | 1 | 2014 | 2 | 0.120 |
Why?
| Eye Neoplasms | 1 | 2014 | 10 | 0.120 |
Why?
| Siblings | 1 | 2014 | 33 | 0.120 |
Why?
| Vision, Monocular | 1 | 2013 | 1 | 0.110 |
Why?
| Injections, Intraocular | 1 | 2013 | 2 | 0.110 |
Why?
| Liver Neoplasms | 1 | 2018 | 329 | 0.110 |
Why?
| Diagnostic Techniques, Ophthalmological | 1 | 2013 | 11 | 0.110 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 78 | 0.110 |
Why?
| Molecular Biology | 2 | 2023 | 25 | 0.110 |
Why?
| Cell Line | 1 | 2016 | 1010 | 0.110 |
Why?
| GTP-Binding Proteins | 2 | 2023 | 93 | 0.110 |
Why?
| Treatment Outcome | 4 | 2020 | 5178 | 0.100 |
Why?
| Postoperative Complications | 2 | 2024 | 1018 | 0.100 |
Why?
| Activities of Daily Living | 1 | 2013 | 174 | 0.100 |
Why?
| Autistic Disorder | 1 | 2013 | 122 | 0.100 |
Why?
| Diet | 1 | 2016 | 553 | 0.100 |
Why?
| Rats, Inbred Lew | 1 | 2011 | 43 | 0.100 |
Why?
| Administration, Topical | 1 | 2011 | 56 | 0.100 |
Why?
| Endotoxins | 1 | 2011 | 31 | 0.100 |
Why?
| Cornea | 1 | 2011 | 51 | 0.090 |
Why?
| Referral and Consultation | 1 | 2013 | 285 | 0.090 |
Why?
| Pseudomonas aeruginosa | 1 | 2011 | 71 | 0.090 |
Why?
| Membrane Proteins | 2 | 2023 | 347 | 0.090 |
Why?
| Mice, Inbred C57BL | 1 | 2016 | 1777 | 0.090 |
Why?
| Mice | 2 | 2022 | 5658 | 0.090 |
Why?
| RNA | 1 | 2011 | 169 | 0.090 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 579 | 0.090 |
Why?
| Magnetic Resonance Imaging | 2 | 2014 | 1526 | 0.080 |
Why?
| Angiogenesis Inhibitors | 2 | 2020 | 182 | 0.080 |
Why?
| Cytokines | 1 | 2011 | 607 | 0.080 |
Why?
| Lens Implantation, Intraocular | 2 | 2018 | 25 | 0.080 |
Why?
| Cross-Sectional Studies | 1 | 2013 | 1574 | 0.080 |
Why?
| Aged, 80 and over | 3 | 2020 | 3137 | 0.080 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2007 | 3 | 0.070 |
Why?
| Orbital Cellulitis | 1 | 2007 | 9 | 0.070 |
Why?
| Corneal Diseases | 1 | 2007 | 14 | 0.070 |
Why?
| Microsurgery | 1 | 2007 | 30 | 0.070 |
Why?
| Fungi | 1 | 2007 | 47 | 0.070 |
Why?
| Cross Infection | 1 | 2007 | 94 | 0.070 |
Why?
| Lipids | 2 | 2022 | 145 | 0.070 |
Why?
| Aptamers, Nucleotide | 1 | 2006 | 6 | 0.070 |
Why?
| Prosthesis-Related Infections | 1 | 2007 | 106 | 0.060 |
Why?
| Diagnostic Imaging | 1 | 2007 | 179 | 0.060 |
Why?
| Vitamins | 1 | 2006 | 64 | 0.060 |
Why?
| Bacteria | 1 | 2007 | 219 | 0.060 |
Why?
| Vitreous Body | 2 | 2002 | 20 | 0.060 |
Why?
| Rats | 1 | 2011 | 3273 | 0.060 |
Why?
| Limbus Corneae | 1 | 2024 | 9 | 0.060 |
Why?
| Microvessels | 1 | 2024 | 29 | 0.060 |
Why?
| Lens, Crystalline | 1 | 2024 | 20 | 0.060 |
Why?
| Atrophy | 1 | 2023 | 38 | 0.060 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 13 | 0.050 |
Why?
| Recovery of Function | 1 | 2023 | 187 | 0.050 |
Why?
| Optic Nerve | 1 | 2022 | 50 | 0.050 |
Why?
| Cytomegalovirus Retinitis | 1 | 2002 | 2 | 0.050 |
Why?
| Injections | 1 | 2002 | 56 | 0.050 |
Why?
| Smoking | 1 | 2006 | 506 | 0.050 |
Why?
| Chromatography, Liquid | 1 | 2022 | 225 | 0.050 |
Why?
| Tandem Mass Spectrometry | 1 | 2022 | 227 | 0.050 |
Why?
| Diagnosis, Differential | 2 | 2007 | 1037 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2023 | 584 | 0.040 |
Why?
| Health Status Disparities | 1 | 2023 | 196 | 0.040 |
Why?
| Hypertension | 1 | 2006 | 531 | 0.040 |
Why?
| Vibration | 1 | 2000 | 14 | 0.040 |
Why?
| Retinal Vein | 1 | 2000 | 3 | 0.040 |
Why?
| Retinal Artery | 1 | 2000 | 5 | 0.040 |
Why?
| Epiretinal Membrane | 1 | 2020 | 10 | 0.040 |
Why?
| Iris | 1 | 2000 | 6 | 0.040 |
Why?
| Conjunctiva | 1 | 2000 | 14 | 0.040 |
Why?
| Healthcare Disparities | 1 | 2023 | 282 | 0.040 |
Why?
| Mitochondria | 1 | 2022 | 395 | 0.040 |
Why?
| Fatty Acids | 1 | 2000 | 143 | 0.040 |
Why?
| Cholesterol | 1 | 2000 | 148 | 0.040 |
Why?
| Occupational Diseases | 1 | 2000 | 82 | 0.040 |
Why?
| Triglycerides | 1 | 2000 | 152 | 0.040 |
Why?
| State Medicine | 1 | 2018 | 14 | 0.040 |
Why?
| Equipment Design | 1 | 2019 | 286 | 0.040 |
Why?
| Pseudophakia | 1 | 2018 | 12 | 0.040 |
Why?
| Developing Countries | 1 | 1998 | 56 | 0.040 |
Why?
| Time-to-Treatment | 1 | 2018 | 70 | 0.040 |
Why?
| Comorbidity | 1 | 2018 | 610 | 0.030 |
Why?
| Video Recording | 1 | 2016 | 79 | 0.030 |
Why?
| Drug Combinations | 1 | 2016 | 126 | 0.030 |
Why?
| Electronic Health Records | 1 | 2018 | 209 | 0.030 |
Why?
| Prospective Studies | 2 | 2000 | 2345 | 0.030 |
Why?
| Pilot Projects | 1 | 1998 | 702 | 0.030 |
Why?
| Time Factors | 1 | 2019 | 2891 | 0.030 |
Why?
| Electrooculography | 1 | 2007 | 14 | 0.020 |
Why?
| Inclusion Bodies | 1 | 2007 | 18 | 0.020 |
Why?
| Lymphocytes | 1 | 2007 | 154 | 0.020 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2007 | 194 | 0.020 |
Why?
| Fibroblasts | 1 | 2007 | 352 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2007 | 1153 | 0.010 |
Why?
| Corneal Opacity | 1 | 2000 | 3 | 0.010 |
Why?
| Trabecular Meshwork | 1 | 2000 | 4 | 0.010 |
Why?
| Pigmentation Disorders | 1 | 2000 | 6 | 0.010 |
Why?
|
|
Uwaydat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|